Absci Corporation (ABSI) is a biological company indulged in machine learning and synthetic biology to enhance the medicinal potential of different proteins. The company formulates next-generation protein-based drugs, which also include Bionic Proteins which contain nonstandard amino acids and other innovative drug platforms. The company identifies novel drug targets and develops the cell lines to make them in a single effective process.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
The price of ABSI stock during the regular trading on January 7, 2022, was $7.19 with a remarkable increase of 17.10%. At last check in the premarket on January 10, 2022, the stock was down by 4.87%.
ABSI: Events and Happenings
On January 07, 2022, ABSI reported about its entry into a partnership with Merck. Under the terms of the partnership, ABSI will utilize its Bionic Protein technology for the production of enzymes customized to Merck’s bioproduction applications. Additionally, Merck could nominate approximately three targets and pave its way for entry into a drug discovery partnership. Under these conditions, ABSI could receive approximately $610 million in fees and milestone payments for the three targets.
ABSI: CEO Comments
Speaking at the occasion, Sean McClain, CEO of ABSI said that the establishment of a partnership with Merck and working with the internationally acclaimed research organization for the generation of innovative enzymes is a moment of pride for the company. He further added that the company is looking forward to creating new biologic candidates to improve patients’ lives.
On January 05, 2022, ABSI reported that the company’s Executives will present at the Virtual 40th Annual J.P. Morgan Healthcare Conference being held on January 10, 2022. On December 30, 2021, ABSI reported that the company’s Executives will present at the Virtual H.C. Wainwright BIOCONNECT Conference being held on January 10, 2022.
ABSI: Key Financials
On November 09, 2021, ABSI reported its financial results for the quarter ended September 30, 2021. Some of the key updates are as follows
Revenue and Assets
Revenue for Q3 2021 was $1.5 million as compared to $0.9 million for the same period of 2020. Total current assets of the company for Q3 2021 were $300 million.
Net Loss per Share
Basic and diluted net loss per share for Q3 2021 was $23.6 million or $0.33 per share, as compared to $3.7 million or $0.85 per share for the corresponding prior-year period.
On October 28, 2021, ABSI reported its Executives’ presence at the virtual investor conferences namely Credit Suisse 30th Annual Healthcare Conference held on November 9 and Stifel 2021 Healthcare Conference held on November 16, 2021. On October 6, 2021, ABSI reported about partnering with EQRx for the developmental activities of protein-based treatments at a reasonable price.
The stock of ABSI is 66% down compared to the past six months because of prevailing pandemic conditions which slowed down the economic conditions. The company showed a remarkable boom in the stock price during the regular trading session due to its announcement of a collaboration with Merck. The company’s stock again decelerated in the premarket due to an uncertain market environment. The experts hope that the company’s recent announcement will be advantageous for the futuristic partnerships.